

20 Nov 2022 | News

# Quick Listen: Scrip's Five Must-Know Things

by

In this week's podcast edition of Five Must-Know Things: a market snapshot of inflammatory bowel disease; will biotech bounce back in 2023?; Phase III miss for Roche's Alzheimer's candidate; how Japan's top firms did in the quarter; and China showcase hints at policies and strategies.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 18 November 2022, including: a market snapshot of inflammatory bowel disease; will biotech bounce back in 2023?; Phase III miss for [\*Roche Holding AG\*](#)'s Alzheimer's candidate; how Japan's top firms did in the quarter; and China showcase hints at policies and strategies.

This and all our other podcasts are available on the Pharma Intelligence channel on [\*Apple Podcasts\*](#), [\*Google Podcasts\*](#), [\*SoundCloud\*](#), [\*TuneIn\*](#) and [\*Spotify Podcasts\*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[\*IBD Market Snapshot: Changes Ahead, But Current Biologics Are Formidable Competitors\*](#)" - Scrip, 11 Nov, 2022.)

(Also see "[\*After Cutting Back And Clinging On, Will Biotech Bounce Back In 2023?\*](#)" - Scrip, 16 Nov, 2022.)

(Also see "[\*Roche's Alzheimer's Drug Fails In Phase III Giving Eisai/Biogen A Clear Run\*](#)" - Scrip, 14 Nov, 2022.)

(Also see "[\*Japan Q2 Roundup: Mixed Bag For Majors But Forex Provides Boost\*](#)" - Scrip, 10 Nov, 2022.)

(Also see "[\*Show Me CIIE: Can Foreign Pharma Continue Growth Trajectory In Closing China?\*](#)" - Scrip, 10 Nov, 2022.)

[Click here to explore this interactive content online](#) ✨